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Abstract Based on its potent capacity to induce tumor
cell death and to abrogate clonogenic survival, radiother-
apy is a key part of multimodal cancer treatment approa-
ches. Numerous clinical trials have documented the clear
correlation between improved local control and increased
overall survival. However, despite all progress, the efficacy
of radiation-based treatment approaches is still limited by
different technological, biological, and clinical constraints.
In principle, the following major issues can be distin-
guished: (1) The intrinsic radiation resistance of several
tumors is higher than that of the surrounding normal tissue,
(2) the true patho-anatomical borders of tumors or areas at
risk are not perfectly identifiable, (3) the treatment volume
cannot be adjusted properly during a given treatment series,
and (4) the individual heterogeneity in terms of tumor and
normal tissue responses toward irradiation is immense. At
present, research efforts in radiation oncology follow three
major tracks, in order to address these limitations: (1)
implementation of molecularly targeted agents and
‘omics’-based screening and stratification procedures, (2)
improvement of treatment planning, imaging, and accuracy
of dose application, and (3) clinical implementation of
other types of radiation, including protons and heavy ions.
Several of these strategies have already revealed promising
improvements with regard to clinical outcome. Neverthe-
less, many open questions remain with individualization of
treatment approaches being a key problem. In the present
review, the current status of radiation-based cancer treat-
ment with particular focus on novel aspects and develop-
ments that will influence the field of radiation oncology in
the near future is summarized and discussed.
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Introduction
Cancer is the second most frequent cause of death within
developed countries being responsible for 200–400 deaths
per 100,000 people each year. The incidence of cancer is
closely related to age, indicating that the probability of
malignant transformation increases with life span. Addi-
tionally, cancer can evolve due to risk factors, such as
cancer-causing lifestyle habits (e.g., cigarette smoking),
genetic predisposition, and viral infections.
Radiotherapy, the clinical application of ionizing radi-
ation, is one crucial treatment option in modern cancer
therapy apart from surgery and systemic therapy as being
corroborated by the fact that more than 60 % of all cancer
patients receive radiotherapy today. Radiotherapy can be
used in various treatment settings ranging from definitive
strategies to multimodal settings, e.g., in adjuvant and in
neoadjuvant settings, with or without concomitant che-
motherapy. The efficacy of radiotherapy has been proven in
multiple randomized trials and has been described in meta-
analyses that included multiple cancer types. Radiotherapy
can significantly prolong patient survival and improve the
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local control rates of tumors. Furthermore, radiotherapy
can help to avoid surgical amputation and to yield better
cosmesis, and it can be used in palliative settings (Ring-
borg et al. 2003; Delaney et al. 2005).
For the treatment of head and neck cancer, radiother-
apy may be used postoperatively, e.g., for patients with
specific risk factors (Bernier et al. 2004; Cooper et al.
2004), but it has also been proven to be effective as
primary definitive treatment strategy—particularly when
being combined with concomitant chemotherapy (Pignon
et al. 2009). In case of lung cancer, radiotherapy can be
applied stereotactically for the treatment of early forms of
bronchial carcinoma achieving high rates in local control
(Guckenberger et al. 2009; Timmerman et al. 2010), and
for advanced stages, it can be used in a neoadjuvant,
adjuvant, or definitive manner as well as for palliation,
respectively (Auperin et al. 2010; Albain et al. 2009;
Douillard et al. 2006). For breast cancer, it was shown
that breast-conserving surgery in combination with adju-
vant radiotherapy results in survival rates that are equal to
mastectomy (Fisher et al. 2002) and that omitting adju-
vant radiotherapy causes a decrease by 4 % in patient
survival (Darby et al. 2011). Finally, in case of prostate
cancer, radiotherapy with or without combined hormone
therapy reveals comparable cure rates as surgical treat-
ment efforts (Bolla et al. 2002), albeit randomized trials
are missing. Taken together, all these findings demon-
strate the importance of radiotherapy as one of today’s
crucial cancer treatment strategies, and the evidence for
its effectiveness is still expanding.
Technical improvements in precision of radiotherapy
Since ionizing radiation is extremely effective in killing
any kind of eukaryotic cell, a relevant therapeutic gain is
only obtained when several prerequisites are met: adequate
fractionation, optimal target delineation, radiation plan-
ning, image guidance, and toxicity diversification (radio-
chemotherapy). In recent years, intensity-modulated
radiotherapy (IMRT) and image-guided radiotherapy
(IGRT) comprise the most important technological
advances (Fig. 1).
Intensity-modulated radiotherapy (IMRT) and
image-guided radiotherapy (IGRT)
In principle, all radiation techniques that employ a non-
homogenous photon fluence over a given radiation field
can be considered as ‘‘intensity modulated.’’ In a more
narrow sense, IMRT describes the sequential accumulation
of multiple radiation fields resulting in a non-homogenous
photon fluence from different gantry angles (Glatstein
2002). Currently, several variations in the IMRT principle
are being used to achieve highly conformal radiation dis-
tributions: Classical IMRT, volumetric-modulated arc
therapy (VMAT), Rapid Arc, Tomotherapy, and Cyber-
knife are different technological/vendor-specific solutions
that are used to achieve optimal dose distributions while
sparing normal tissues in an optimal fashion. To date, it has
been proven that the use of IMRT achieves better confor-
mity of the high-dose region to the target volume when
compared to 3D conformal approaches, especially for
complex treatment situations (Bortfeld 1999), in which
adjacent organs at risk might compromise full coverage of
the target volume (Mok et al. 2011).
Up to now, many trials have been performed docu-
menting the feasibility of increased target doses with
reduced toxicity using IMRT. Probably, the best examples
are sparing of the parotid gland in head and neck cancer
(Hey et al. 2011) and sparing of the rectum and the bladder
while concomitantly increasing the target dose in prostate
Fig. 1 Improvements in
clinical radiotherapy with
decisive impact in recent years
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cancer (Takeda et al. 2012). However, randomized data
that compare IMRT with classical 3D conformal radio-
therapy are rare (Gupta et al. 2012). This is clearly related
to the fact that it is difficult to set up a randomized trial
whenever obvious differences in high-dose distributions
are visible already after radiation plan comparison. In the
meantime, more advanced rotational IMRT techniques
such as VMAT and RapidArc have entered clinical
practice and allow for even faster application of prescribed
doses. However, the clinical benefits of these techniques
need to be further investigated (Jiang et al. 2011; Wiezorek
et al. 2011; Foroudi et al. 2012; Fogarty et al. 2011). At
present, the development strategies in the field of IMRT
and related techniques basically aim at further improving
the underlying planning and optimization algorithms as
well as the technology of the LINACs in use. However,
several open issues are not yet fully solved: (1) dose
optimization in case of non-homogenous dose distribu-
tions, (2) toxicity prediction in case of non-homogenous
doses to organs at risk, (3) reproducibility and verification
of treatments with strongly increasing degrees of freedom
(rotation, rotation speed, dose rate, field shape, etc.), and
(4) mechanical stability and reliability of all components in
use. Therefore, one focus of research is the development of
planning algorithms, including tools for biological opti-
mization and improved dose calculation (Monte Carlo
calculations or similar). In addition, the technology pro-
viders aim at developing LINACs that are more and more
‘‘ab initio’’ designed for the implementation of the tech-
nologies mentioned above. In parallel, with increasing
precision of radiation planning and dose application, the
need for better target acquisition raises strongly. The term
‘‘target acquisition’’ covers merely all aspects of patient
positioning, patient movement, internal organ movement
between fractions, and internal organ motion within a
fraction. In this regard, many different visualization tools
are in use or in clinical testing. IGRT tools range from
classical electronic portal imaging devices (EPIDs) (Njeh
et al. 2012) and MV and kV cone-beam CTs (Foster et al.
2012) to complex 3D ultrasound (Chadha et al. 2011) and
surface scanners (Pallotta et al. 2012). The wide use of
these imaging devices will change the classical target
volume approaches considerably. To date, the gross target
volume (GTV) -[ clinical target volume (CTV) -[ plan-
ning target volume (PTV) concept is rather static using
predefined safety margins in order to compensate for any
kind of movement. Replacing this paradigm by daily
‘‘online’’ controls allows for smaller margins, which only
reflect biological uncertainties.
In a wider sense, the term ‘‘IGRT’’ describes the use of
advanced imaging technology, in order to optimally define
target volume sites and organs at risk. At present, several
imaging modalities have entered clinical practice in
radiation oncology. 18F-Fluorodeoxyglucose (FDG)-based
positron emission tomography (PET)-CT is frequently
helpful during target volume definition. Highly specific
PET markers such as tetraazacyclo-dodecane-tetraacetic
acid (DOTA)-octreotide (DOTATOC) and DOTA-octreo-
tate (DOTATATE) strongly improve the definition of the
target volume for meningioma (Gehler et al. 2009). Even
less specific markers (e.g., 18F-fluoroethyltyrosine (FET)-
PET) may strongly influence radiation treatment planning
for glioma patients. In this regard, several groups have
shown that FET-PET alters treatment volumes in roughly
50 % of the cases (Niyazi et al. 2012b). Nevertheless,
many issues are currently unsolved: Specificity and sensi-
tivity of merely all tracers are not high enough to allow for
automated segmentation of the target volumes. Besides
PET-CT, other means of advanced imaging also influence
target volume delineation in radiation oncology. At pres-
ent, the definition of the adjuvant lymphatic drainage
region follows empiric and pragmatic rules (Vorwerk and
Hess 2011) rather than individual patient-oriented consid-
erations. For the prostate, several groups have analyzed the
feasibility of SPECT-based sentinel analysis to define
individual lymphatic regions at risk (Vees et al. 2012;
Ganswindt et al. 2007). Similarly, more specific MRI
tracers would be of key importance for improved target
volume definition in various disease sites (Weidner et al.
2011). Thus, it is clear that the combination of improved
imaging, both for delineation of the target volume and
during treatment, will play a key role in future radiation
oncology (Xing et al. 2006). In this regard, the use of IGRT
results already today in less acute toxicity during radio-
therapy, e.g. in case of prostate cancer (Gill et al. 2011;
Crehange et al. 2012).
Protons and heavy ions
Several recent developments like IMRT allow for the
reduction in the dose exposed to normal tissue while
keeping the prescribed dose on the tumor volume. How-
ever, these methods come at the cost of increasing the
volume of normal tissues receiving low or moderate doses,
and it has been assumed that this may increase the risk of
radiation-induced secondary cancers (Hall 2009) although
clinical or epidemiological data are not available yet.
Charged particles such as protons or heavy ions deliver the
highest dose near the end of their range, in the so-called
Bragg peak. This allows for extremely steep dose gradients
distal to the Bragg peak and thus for superior sparing of
organs at risk in the vicinity of the target. Because there is,
apart from a dose that is due to secondary particles or
fragments, no exit dose and because entrance doses are
lower than in the case of photons, this allows for an overall
reduction in the integral dose outside the planned target
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area, which is expected to significantly reduce the risk of
radiogenic secondary malignancies in long-term cancer
survivors (Fontenot et al. 2010; Newhauser and Durante
2011). So far, no long-term epidemiological studies on the
incidence of secondary cancer cases following a proton- or
a heavy ion-based cancer treatment are available, and given
the latency period associated with radiation-induced
tumors, these studies will also not be available in nearer
future. The knowledge of radiation-induced tumorigenesis
and the many parameters involved (e.g., radiation dose and
quality, fractionation, age at exposure, genetic suscepti-
bility) is limited, and therefore, risk estimations are diffi-
cult to perform. For example, passive beam scattering,
which has been the predominant method for increasing the
size of the proton pencil beam generated by the accelerator
up to now, produces secondary neutrons with a broad range
of energies for some of which the relative biological
effectiveness (RBE) is poorly characterized (Hall 2009),
and therefore, the impact of these neutrons on secondary
tumor risk is difficult to estimate. It should be noted that
part of secondary neutron production is reduced in particle
therapy setups using active beam scanning (Clasie et al.
2010).
So far, only a few clinical studies have been performed
on the efficacy and acute side effects of proton and ion
therapy, and only very few of them have directly compared
the outcome of particle therapy and conventional radio-
therapy. Brada et al. (2009) gave a detailed overview on the
clinical impact of proton therapy based on a search within
published, peer-reviewed literature. They identified 52
studies of proton therapy fulfilling their quality criteria (at
least 20 patients with a follow-up period of at least
2 years), encompassing data of in total 13,736 patients
(Brada et al. 2009). Of these patients, 10,328 received
treatments for ocular tumors and 1,642 were treated for
prostate tumors and 880 for tumors of the central nervous
system (CNS). Other tumor entities such as head and neck
tumors, gastrointestinal tumors, lung cancer, and sarcomas
were subjects of two to five studies each, encompassing
between 97 and 375 patients per tumor site. This number
must be compared to more than 60,000 patients who
had undergone a proton-based cancer therapy by the end
of 2008 (http://ptcog.web.psi.ch/Archive/Patientstatistics-
update02Mar2009.pdf). Brada and coauthors concluded
that the evaluated literature lacks any evidence demon-
strating a clear benefit of proton-based therapy if compared
to the best available conventional therapies with respect to
tumor control, patient survival, and side effects. Others
studies came to similar conclusions, even with respect to
pediatric tumors (Bouyon-Monteau et al. 2010), prostate
cancer (Kagan and Schulz 2010), lung cancer (Liao et al.
2011), head and neck cancers (Ramaekers et al. 2011), and
tumors of the skull base treated by radiosurgery (Amichetti
et al. 2012). A recent study even showed higher rates of
gastrointestinal side effects after a proton-based therapy if
compared to conventional IMRT of prostate cancer (Sheets
et al. 2012), but the methodology applied in this study is
under debate (Deville et al. 2012; Mendenhall et al. 2012;
Jacobs et al. 2012). Clearly, the absence of evidence is not
evidence of absence of a superior efficacy or tolerance of
proton therapy, but nevertheless, these analyses clearly
stress the requirement of more clinical studies assessing the
clinical impact of proton-based cancer therapy.
The better the conformity, the higher are the require-
ments for setup reproducibility, accuracy in patient
immobilization, and consideration of changes in the
patient’s anatomy, such as the motion of organs (e.g., due
to filling of the bladder or the rectum), or treatment-
induced alterations, e.g., tumor shrinkage. This holds for a
highly conformal therapy with both photons and protons.
The impact of intrafraction mobility, which is affected by
the duration of the treatment, may be of special importance
in case of an active proton beam scanning, because this
method takes considerably more time than passive scat-
tering or photon irradiation. Importantly, in the case of
protons, an additional level of complexity comes into play
since absorption and scattering of protons largely depend
on the material traversed so that the range and the lateral
penumbra are affected by the inhomogeneity of the tissue.
Uncertainty in estimating the particle range will automat-
ically translate into dose uncertainties. In spite of demands
for state-of-the-art imaging, image guidance, and dose
verification, several authors raised concerns about the lack
of optimal technologies at proton therapy facilities (Mer-
chant 2009; Schippers and Lomax 2011). As already
pointed out by Goitein in 2008, the possibility for treatment
errors is much greater in case of protons than with photons
and therefore, proton therapy has to be used exclusively in
a highly controlled fashion (Goitein 2008).
Carbon ions are less affected by energy straggling and
scattering as compared to protons, and therefore, the
precision of the dose deposition achievable is even greater
than in the case of protons. However, due to fragmenta-
tion processes, a dose tail is always present distally from
the Bragg peak, which must be considered in treatment
planning. These fragmentation processes come, however,
also with an advantage, namely the generation of positron
emitters that allow for in situ beam monitoring (Weber
and Kraft 2009). One major potential of carbon ions lies
in the fact that they can confer a significant higher RBE
than photons within their Bragg peak region, and this not
only means that the physical dose there is highest, but
also the biological effect achievable per dose unit. The
expenses for carbon-ion-based radiotherapy units are,
however, even greater than for proton facilities, and only
few facilities have been available in the past. Since 2009,
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the carbon ion radiotherapy unit at the Heidelberg Ion
Therapy (HIT) center which uses active beam scanning is
operating, and initial data on clinical experiences become
available now (Combs et al. 2010b). At HIT, all patients
are treated within clinical trials (Combs et al. 2010a, c;
Jensen et al. 2011a, b), and recently, randomized phase III
trials have been initiated to compare proton- and carbon-
ion-based therapies for the treatment of chondrosarcomas
and chordomas (Nikoghosyan et al. 2010a, b). Due to
their higher RBE, the treatment with carbon ions might be
more effective for the cure of radioresistant tumors. A
recent meta-analysis performed in different head and neck
cancers compared the efficacies of photons, protons, and
carbon ions (Ramaekers et al. 2011) but, so far, only
revealed a survival benefit for mucosal malignant mela-
nomas after a carbon-ion-based therapy, which might
reflect a high grade of resistance of this particular tumor
entity toward irradiation in general. Other work suggests
that due to the reduced volume of normal tissue that is
exposed to modest doses, particle therapy may confer
advantages in treatments using concurrent drug adminis-
tration (Nystrom 2010). In a modeling study, Vogelius
et al. (2011) estimated the pneumonitis risk after a
treatment with photons or protons either in combination
with or in the absence of chemotherapy and came to the
conclusion that proton therapy could potentially minimize
the risk by reducing the volume that is exposed to lower
doses (Vogelius et al. 2011). Given the increasing role of
multimodality treatment approaches, further investigations
into the relative merit of particle therapy in these settings
are clearly needed.
The controversial discussion on the necessity of clin-
ical studies of particle therapy is, in part, fuelled by the
high costs of this treatment if compared to established
photon therapy. One part of such elevated costs is due to
the size of the synchrotrons or cyclotrons used, and there
are several developments that aim for provision of
smaller accelerators (Schippers and Lomax 2011). One
putative solution could be the acceleration of protons and
also of heavier ions by laser acceleration (Tajima 2010).
Although current technologies are far from clinical
application, some research groups already started to
address the question of whether the RBE of laser-driven
particles may differ from that of conventionally acceler-
ated particles, thereby focusing on the ultrashort pulsing
process by which these particles are generated as well as
on the ultra-high dose rates associated with it (Rigaud
et al. 2010; Yogo et al. 2009; Kraft et al. 2010; Bin et al.
2012). By simulating the pulsed radiation conditions
expected in therapy settings using laser-accelerated pro-
tons of a pulsed proton beam at the Munich ion micro-
beam SNAKE (Dollinger et al. 2009), an extensive series
of experiments with various endpoints in cell monolayers,
3D tissue culture models, and tumor xenografts were
conducted. However, no significant differences between a
dose of a few Gy that was given in about 1 ns (the dose
rate expected after laser acceleration) and the same dose
given in about 100 ms (the dose rate at conventional
irradiation settings) could be observed in these experi-
ments (Schmid et al. 2009, 2010; Auer et al. 2011;
Greubel et al. 2011; Zlobinskaya et al. 2012).
Biological improvements of radiotherapy
During the last decades, significant improvements have
been made: A special focus has been placed on the
development of advanced planning procedures (van Herk
2004), the physical accuracy of dose application (Bucci
et al. 2005) and combined modality treatment approaches
in terms of radiochemotherapy (Al-Sarraf et al. 1998)
(Fig. 1). However, dose escalation studies revealed that the
combination of radiotherapy with classical chemotherapy
has reached some kind of dead end (Budach et al. 2006). At
this point, the combination of radiotherapy with molecu-
larly designed agents specifically targeting the hallmarks of
cancer has revealed significant improvements in clinical
outcomes when compared to each treatment strategy alone
(Begg et al. 2011). However, the effective integration of
molecularly targeted drugs requires a detailed patient
stratification, since only those patients with relevant signal
aberrations will benefit. Furthermore, it has to be noted that
stratification is urgently needed in order to avoid side
effects induced by the addition of such targeted drugs
(Niyazi et al. 2011b). In the following paragraphs, the key
biological targets for specifically improved radiotherapy
will be introduced.
The hallmarks of cancer
The emergence of cancer, in general, is due to failures
within mechanisms or pathways that control the growth,
the proliferation, and/or the death of cells in response to
extracellular or intracellular signals. Deregulations within
these mechanisms can commit cells to sustained prolif-
eration, replicative immortality, evasion of growth sup-
pression, and resistance to cell death—attributes
commonly shared by malignantly transformed cells
(Hanahan and Weinberg 2000). However, the transition
from a single transformed cell toward the formation of a
solid tumor requires additional features, such as the
capacity to instigate the formation of blood vessels
(angiogenesis and/or neovascularization), mechanisms to
evade immune responses, as well as an increased poten-
tial to invade other tissues (metastasis) (Hanahan and
Weinberg 2011).
Radiat Environ Biophys (2014) 53:1–29 5
123
Sustained proliferation and replicative immortality
The growth as well as the proliferation of cells is orches-
trated by a class of signaling molecules called mitogens.
While in non-transformed cells, the synthesis and the
release of mitogens are tightly controlled, these processes
are often deregulated in cancer cells. Such deregulation can
be due to the acquisition of genetic mutations (for instance
due to exposure to tumor-initiating chemicals and/or ion-
izing radiation) or to the experience of growth-supporting
signals, such as tumor-promoting chemicals and chronic
inflammation. Two of the best-characterized mitogens are
the platelet-derived growth factor (PDGF) and the epider-
mal growth factor (EGF). The binding of these ligands to
their respective receptors, PDGFR and epidermal growth
factor receptor (EGFR), activates sophisticated signaling
pathways, including the mitogen-activated kinase (MAP
kinase) pathway, thereby stimulating both the growth and
the proliferation of cells (Seger and Krebs 1995). Muta-
tions within the genes that encode for such mitogens/
receptors can render the corresponding gene products in a
state of constitutive activation culminating in uncontrolled
growth and/or proliferation of cells. In this regard, the gene
encoding the small GTPase K-Ras provides a prototypical
example as activating mutations of K-Ras are found in
diverse cancer entities, e.g., in more than 40 % of all
colorectal cancers (Karapetis et al. 2008). Similar examples
can be found in other mitogenic signaling pathways,
including the phospho-inositide-3-kinase (PI3 K)/AKT
kinase and the insulin-like growth factor (IGF) pathway
(Chang et al. 2003; Fresno Vara et al. 2004; Samani et al.
2007; Frasca et al. 2008).
With regard to their impact on the outcome of radio-
therapy, both overexpression and mutation of EGFR were
shown to correlate with increased resistance of tumors to
irradiation and poor clinical prognosis (Lammering et al.
2003, 2004; Giralt et al. 2005; Milas et al. 2004). Fur-
thermore, ligand-independent activation of EGFR in
response to irradiation and the subsequent activation of its
downstream signaling cascades apparently contribute to
radioresistance (Iyer et al. 2004; Gupta et al. 2001; Toulany
et al. 2005). Therefore, multiple strategies have been
developed in order to interfere with EGFR function as
being discussed in more detail later on.
A key step in malignant transformation is the acquire-
ment of basically limitless replicative potential. After a
certain number of division cycles, a normal cell exits the
cell cycle and transits into senescence, a stage of metabolic
activity devoid of further proliferation (Campisi and
d’Adda di Fagagna 2007). The induction of senescence
requires a group of proteins encoded by genes that are
known as tumor-suppressor genes (e.g., p53, pRB). These
genes negatively regulate the growth and/or the
proliferation of cells, and hence, mutations that render their
products inactive can support both immortalization and
unrestrained proliferation. Another prerequisite for repli-
cative immortality is the cell’s capacity to protect its
telomeres (Blasco 2005). Since expression of telomerase is
almost absent in non-immortalized cells, their replicative
potential is greatly limited by successive telomere short-
ening. In immortalized cells (including cancer cells), to the
contrary, expression of telomerase is reinitiated, thereby
counteracting the erosion of telomeres and, in conse-
quence, the induction of senescence or apoptosis. Addi-
tionally, expression of telomerase and telomere length have
been reported to contribute to radioresistance of tumor cells
(Genesca et al. 2006).
Evasion of growth suppression and resistance to cell death
Aside from extensive proliferation, the formation of solid
tumors necessitates the cellular capacity for evading
growth-suppressive signals, which mostly depend on
tumor-suppressor proteins, such as p53 or the members of
the retinoblastoma protein family. These proteins interfere
with cell proliferation in response to growth-inhibiting
signals and/or intracellular disorders including DNA
damage either by blocking the expression of genes required
for cell cycle progression or by initiating the expression of
cell cycle-inhibiting genes such as p16INK4a and p21WAF1
(Sherr and Roberts 1999). Alternatively, tumor-suppressor
proteins (in particular p53) can also stimulate the induction
of a programmed form of cell death called apoptosis, e.g.,
in response to DNA damage, explaining p53’s pivotal role
in determination of tumor radiosensitivity (Gudkov and
Komarova 2003). In this context, p53 induces the expres-
sion of several pro-apoptotic proteins (e.g., PUMA) and
thereby facilitates the induction of apoptosis. However,
many cancer cells circumvent apoptosis, e.g., by inacti-
vating p53, by down-regulating pro-apoptotic genes, or by
up-regulating antiapoptotic genes.
Angiogenesis and neovascularization
Since the formation of solid tumors demands for a con-
tinuous nutrient and oxygen supply, tumor cells must
acquire the capacity to stimulate vascularization involving
de novo formation of blood vessels (vasculogenesis) as
well as sprouting of newly formed vessels from preexisting
ones (angiogenesis). In adults, angiogenesis and vasculo-
genesis are tightly limited to certain physiological pro-
cesses, such as wound healing. However, during tumor
progression, angiogenesis is reinitiated (Bergers and Ben-
jamin 2003). To this end, tumor cells secrete pro-angio-
genic factors, such as the vascular endothelial growth
factor (VEGF) that, upon binding to their respective
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receptors (VEGFR), stimulate the proliferation of endo-
thelial cells resulting in increased vessel formation and
tumor infiltration. VEGF expression in tumor cells is
facilitated by certain oncogene products, including c-Myc
or H-Ras, whereas non-transformed cells express VEGF
almost exclusively under hypoxic conditions (Baudino
et al. 2002; Chin et al. 1999). The degree of vascularization
plays an important role in regard to the tumor’s respon-
siveness to ionizing radiation. As the induction of DNA
damage is supported by the presence of oxygen, increased
hypoxia limits the efficacy of radiotherapy. Consequently,
intense efforts are spent in order to increase tumor oxy-
genation and to improve the therapeutic effect of exposure
to ionizing radiation (Wachsberger et al. 2003).
Evasion of immune responses
Another barrier limiting the formation and the progression
of tumors is the immune system. This becomes clear by the
fact that immunocompromised mice, e.g., mice that are
deficient in CD8? T lymphocytes or natural killer (NK)
cells, show a significant higher susceptibility to cancer than
those that are immunocompetent (Schreiber et al. 2011).
Consequently, it is no wonder that tumor cells acquire
multiple mechanisms to evade immune responses, such as
elimination and/or aberration of tumor antigens/MHC class I
molecules, secretion of immunosuppressive cytokines such
as transforming growth factor b (TGF-ß) and interleukins,
recruitment of immunosuppressive immune cells (e.g.,
CD4? CD25? regulatory T cells and myeloid-derived sup-
pressor cells), or expression of indolamine-2,3-dioxygenase
(IDO) (Kaufman and Disis 2004; Munn and Mellor 2007;
Garcia-Lora et al. 2003). Several lines of evidence support
the notion that the immune system plays a pivotal role in
tumor regression in response to radiotherapy (Lauber et al.
2012). This is of particular interest, since the induction of an
antitumor immune response might not only be helpful for
the elimination of the primary tumor within the irradiation
field, but also for out-of-field metastases (Frey et al. 2012).
Tissue invasion and metastasis
Aside from their capacity to form primary tumors, some
malignantly transformed cells also acquire the capacity to
infiltrate neighboring tissues or even penetrate lymphatic
and/or blood vessels, giving rise to several kinds of sec-
ondary tumors or metastases. Usually, metastasis starts
with the detachment of tumor cells from the primary tumor
site facilitated by the repression of factors that mediate
cellular adhesion, such as E-cadherin, and by secretion of
enzymes that degrade extracellular matrices (ECMs), thus
liberating tumor cells from their surroundings (Valastyan
and Weinberg 2011). These processes depend on the
activation of a conserved cellular program termed the
epithelial–mesenchymal transition (EMT), which regulates
the formation of the mesoderm and the neural tube during
embryonic development (Thiery et al. 2009). For several
tumor entities, glioblastomas in particular, it was shown
that irradiation increases their invasive potential and thus
might even accelerate local dissemination and development
of distant metastasis (Qian et al. 2002; Cordes et al. 2003;
Wild-Bode et al. 2001; Camphausen et al. 2001).
Mechanisms of cell death
Radiotherapy is an important treatment modality in clinical
cancer therapy because of its great potential to kill
malignant cells and to abrogate clonogenic survival.
Directly or indirectly, ionizing radiation induces different
types of genome damage, including DNA double-strand
breaks (DSBs), bulky lesions, and others, thereby activat-
ing a highly sophisticated signaling network termed the
DNA damage response (DDR) culminating in transient or
permanent cell cycle arrest and/or cell death, respectively
(Fig. 2).
DNA damage response (DDR)
The DDR mediates cellular responses to various kinds of
DNA damage, a cell has to cope with. The DDR is regu-
lated by two conserved protein kinases called Ataxia tel-
angiectasia mutated (ATM) and Ataxia telangiectasia and
Rad3 related (ATR) (Smith et al. 2010). ATM is recruited
to DSBs by the Mre11-Rad50-Nbs1 (MRN) complex
where it phosphorylates the histone H2 variant H2AX,
thereby creating a recruitment platform for other DDR
factors (Shiloh 2006). In parallel, ATM mediates resection
of the broken DNA strand(s), and the resulting ssDNA
repair intermediates specifically activate ATR kinase
(Hurley and Bunz 2007). By phosphorylation of two
respective downstream kinases termed CHK1 and CHK2,
ATR and ATM trigger a multitude of signaling pathways,
thereby initiating both a transient arrest within cell cycle
progression and DNA damage repair. However, in case of
excessive DNA damage, ATM/ATR can also induce cel-
lular senescence and/or cell death (Jackson and Bartek
2009).
The major target of the ATM/ATR cascade in terms of
arresting the cell cycle or committing the cell to cell death
is the tumor-suppressor protein p53. In the absence of DNA
damage, the overall levels of p53 within the cell are
maintained rather low because of the association of p53
with the ubiquitin ligase MDM2 (HDM2 in human).
MDM2 continuously ubiquitylates p53, thereby targeting
p53 for proteasomal degradation. Yet, in the context of the
DDR, p53 is phosphorylated by kinases of the ATM/ATR
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cascade leading to its dissociation from MDM2 and thus to
stabilization of p53 (Meek 2009). Once being stabilized,
the transcription factor p53 crucially regulates cell cycle
arrest, DNA damage repair, and the induction of cell death
or senescence by inducing or repressing the expression of
several target genes that encode for factors involved in
these processes (Sengupta and Harris 2005).
Apoptosis
Apoptosis is a form of programmed cell death, which is
characterized by chromatin condensation/fragmentation,
cell shrinkage, and blebbing of cell membranes. In
response to irradiation, apoptosis is predominantly
observed in cells of the hematopoietic system. Radiation-
dependent induction of apoptosis mainly relies on the
intrinsic death pathway (Rudner 2001), in which cyto-
chrome c is released into the cytosol by permeabilization of
the outer mitochondrial membrane. This, in turn, stimulates
the formation of the apoptosome and subsequent activation
of the caspase cascade. The cleavage of multiple caspase
substrates within the cell finally results in chromatin
fragmentation, organelle destruction, and cellular disinte-
gration (Taylor et al. 2008). The process of mitochondrial
permeabilization is essentially controlled by pro- and
antiapoptotic members of the B-cell lymphoma-2 (Bcl-2)
family, which regulate the channel-forming activity of the
family members BAX and BAK (Chipuk et al. 2010; Youle
and Strasser 2008). Protein p53 can modulate this equi-
librium in response to DNA damage by inducing the
expression of pro-apoptotic Bcl-2 family members, such as
PUMA, NOXA, and BAX itself (Sengupta and Harris
2005).
Stimulation of apoptosis via the extrinsic death pathway,
on the contrary, depends on the binding of death ligands
(e.g., CD95L, TRAIL) to their respective cell surface
receptors (Debatin and Krammer 2004). Subsequent death
receptor clustering triggers the activation of the caspase
cascade in this pathway. Although the expression levels of
several key regulators of the extrinsic pathway have been
described to increase upon exposure to ionizing radiation
(Belka et al. 1998; Haupt et al. 2003), the intrinsic pathway
appears to be the dominant pathway of apoptosis induction
in response to DNA damage (Rudner 2001). Additionally,
Fig. 2 Mechanisms of cell
death triggered by ionizing
radiation
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it should be noted that cells deficient in p53 function can
undergo radiation-induced apoptosis as well, indicating
that alternative mechanisms such as p63-/p73-dependent
expression of pro-apoptotic factors can compensate for the
lack of p53 in these cases (Afshar et al. 2006; Wakatsuki
et al. 2008).
Necroptosis/Necrosis
When activation of caspases is prevented, DNA damage
can induce an alternate form of cell death termed nec-
roptosis. Necroptosis depends on hyperactivation of the
poly-ADP-ribose-polymerase (PARP), a protein involved
in DNA excision repair, and subsequent activation of
receptor-interacting protein (RIP)—kinases as a response
to depletion of intracellular ATP. Necroptosis, once being
triggered by a structure called the necrosome, is charac-
terized by the appearance of reactive oxygen species
(ROS), lipid peroxidation, failure in calcium homeostasis,
organelle swelling, and plasma membrane rupture (Van-
denabeele et al. 2010). It appears to be of special
importance in cancer cells of epithelial origin which
reveal a limited apoptosis induction capacity in response
to ionizing radiation, and also when irradiation is applied
in high doses or in combination with hyperthermia
(Mantel et al. 2010; Schildkopf et al. 2010). Additionally,
high doses of ionizing radiation can stimulate necrosis, an
accidental, uncontrolled type of cell death, which is pre-
dominantly characterized by rupture of the plasma
membrane and a resulting release of intracellular contents,
including danger signals, which can potently alert the
immune system.
Mitotic catastrophe
The term ‘‘mitotic catastrophe’’ describes a cellular con-
dition, which results from aberrant cell cycle progression
prior to mitotic entry or during cell division itself. Mitotic
catastrophe is characterized by the formation of huge cells
with multiple nuclei as well as hyperamplified centro-
somes. It might constitute the predominant mechanism of
radiation-dependent cell death in cells with defective cell
cycle checkpoints (Eriksson and Stigbrand 2010). How-
ever, cells, which have undergone mitotic catastrophe,
might survive for several days, transit into senescence, or
die by apoptosis and/or necro(pto)sis due to their high
degrees of aneuploidy.
Cellular senescence
Cellular senescence is a state of permanent cell cycle
arrest, which can be instigated by DNA damage. Senes-
cence induction requires function of certain cell cycle
checkpoint components, such as p53 and the retinoblas-
toma protein pRB, but it has also been observed in the
absence of functional p53 (Nardella et al. 2011). Senescent
cells are active in terms of metabolism, but do not show
further cell cycle progression. Central features of senescent
cells comprise a flattened morphology, an increase in
granularity, the up-regulation of cyclin-dependent kinase
inhibitors, and a positive staining for b-galactosidase (SA-
b-Gal). Furthermore, senescent cells have been reported to
release factors that can support as well as inhibit malignant
progression by influencing both the proliferation of
neighboring cells and antitumor immune responses (Krto-
lica et al. 2001; Eriksson and Stigbrand 2010; Coppe et al.
2010).
Autophagy
Autophagy represents a cellular state that is currently being
discussed as both a mechanism of cell death and cell sur-
vival (Apel et al. 2009). It is characterized by the seques-
tration of proteins and/or organelles within huge
autophagic vesicles called autophagosomes. As fusion of
these vesicles with lysosomes leads to the formation of
autophagolysosomes and degradation of their content pro-
viding material for de novo synthesis and regeneration, it is
rather unclear whether autophagy represents a mechanism
of survival or cell death, respectively. Autophagy involves
the activation of multiple protein kinases, including the
class I phosphatidylinositol-3-kinases (PI3 K-I), stress
kinases, and the mammalian target of rapamycin (mTOR)
kinase, and it has been observed in response to exposure to
ionizing radiation (Apel et al. 2008).
Immunological consequences
The induction of tumor cell death and the inhibition of
clonogenic survival by the application of ionizing radiation
are central elements of its therapeutic success. Yet, it is
well accepted that mechanisms involving both the innate
and the adaptive immune system contribute to tumor
regression—particularly in the context of ablative radio-
therapy, where irradiation is applied in high single doses of
10 Gy or more (Lauber et al. 2012). In this regard, local
high-dose radiotherapy of transplanted mouse B16 mela-
noma has been reported to stimulate the generation of
tumor antigen-specific, interferon-c (IFN-c)-producing T
cells (Lugade et al. 2005). Moreover, ablative, but not
fractionated, radiotherapy drastically enhanced T cell
priming in tumor-draining lymph nodes, which was paral-
leled by a regression of the primary tumor as well as dis-
tant, out-of-field metastases in a CD8? T cell-dependent
manner (Lee et al. 2009). Mechanistically, these T cells
apparently have been primed by dendritic cells (DCs),
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which carry ingested tumor material and cross-present it in
the tumor-draining lymph nodes. A recent study showed
that the intratumoral production of type I interferons (IFN-
a/b) in response to ablative radiotherapy is key in this
scenario, since it enhances the cross-presenting capacity of
tumor-infiltrating DCs (Burnette et al. 2011). This cascade
of interferons, where IFN-a/b produced by CD11c? cells
(presumably DCs and macrophages) enhances the cross-
priming activity of CD8a? DCs thereby stimulating the
generation of IFN-c-producing CD8? T cells and, finally,
tumor rejection, is well known from the field of tumor
immunoediting (Diamond et al. 2011; Fuertes et al. 2013).
Here, IFN-a/b and IFN-c contribute on different levels to
the reduction in tumor burden. Whereas IFN-a/b primarily
exerts its effects on macrophages, DCs, and NK cells by
facilitating their activation and maturation and by
enhancing their capacity to induce adaptive immune
responses (Dunn et al. 2006), IFN-c directly affects the
tumor via inhibition of tumor cell proliferation, apoptosis
induction, inhibition of angiogenesis, and an overall
enhancement of tumor immunogenicity (Dunn et al. 2006;
Lugade et al. 2008; Reits et al. 2006). Additionally, IFN-c
contributes to the stimulation of an antitumor immune
response since it is essentially involved in TH1/TC1 cell
responses and exerts similar effects as IFN-a/b in terms of
innate immune cell activation and DC-mediated antigen
cross-presentation (Dunn et al. 2006). This interferon cas-
cade of innate and adaptive immune responses has only
been described in case of ablative but not conventional,
fractionated radiotherapy (Lee et al. 2009), and the ques-
tion that needs to be addressed is why. One feasible
explanation could be that ablative and fractionated radio-
therapy trigger different tumor cell responses in terms of
cell death and/or senescence induction with only high
single-dose irradiation stimulating primary or secondary,
postapoptotic secondary necro(pto)sis or senescence,
respectively. The corresponding cellular releasates, a
complex mixture of danger signals, and the senescence-
associated secretome are well known to be potent inducers
of IFN-a/b and other pro-inflammatory cytokines and
hence could initiate the IFN-cascade described above and
the DC-mediated instigation of antitumor T cell responses
(Coppe et al. 2010; Apetoh et al. 2007; Peter et al. 2010;
Kuilman and Peeper 2009).
Combination of radiotherapy (RTX) with targeted
agents
Despite the technical improvements in cancer radiotherapy
in recent years, the combination of radiotherapy with
classical chemotherapy has reached a dead end (Budach
et al. 2006). Therefore, novel strategies encompassing the
combination of conventional radiotherapy with agents that
are specifically raised against key factors of malignant
transformation have been designed and are currently being
tested (Fig. 3). In the following paragraphs, current efforts
Fig. 3 Survey of valuable targets for combined modality approaches
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made in order to specifically target cellular compounds to
improve the efficacy of clinical radiation oncology in the
future are discussed.
Combination of RTX with agents targeting the DDR
As the cell-death-inducing potential of ionizing radiation is
largely determined by the cells’ capacity to cope with DNA
damage, it is no wonder that both the expression and the
functionality of DDR components have great impact on the
efficacy of radiotherapy. This can be appreciated by the
fact that the expression of DDR components within dif-
ferent tissues often correlates with the resistance or sensi-
tivity of the respective tissue toward irradiation (Peters
et al. 1982; Deacon et al. 1984). Therefore, targeted
pharmaceutical agents, which interfere with proper func-
tion of the DDR, should be suitable to enhance the efficacy
of conventional radiotherapy (Basu et al. 2012; Begg et al.
2011). Indeed, several studies revealed that interfering with
ATM function (e.g., by using small-molecule inhibitors
such as KU-55933) efficiently sensitizes human cancer
cells to irradiation (Hickson et al. 2004; Cowell et al. 2005;
Golding et al. 2009). Similar results have been reported for
inhibitors of other DDR kinases, e.g., the ATR inhibitors
VE-821 and VE-822 (Prevo et al. 2012; Pires et al. 2012;
Fokas et al. 2012) or the CHK1/2 inhibitor AZD7762
(Zabludoff et al. 2008; Mitchell et al. 2010; Morgan et al.
2010). Other targets within the DDR network are the
PARPs as this class of enzymes is involved in repair of
DNA single-strand breaks (SSBs)—a kind of DNA damage
commonly induced by ionizing radiation. Indeed, several
PARP inhibitors, such as olaparib (AZD-2281) and veli-
parib (ABT-888), have revealed great potentials in terms of
sensitizing tumor cells to irradiation in combined modality
approaches (Donawho et al. 2007; Barazzuol et al. 2013;
Miura et al. 2012; Chalmers et al. 2004; Senra et al. 2011;
Shelton et al. 2013) and are, therefore, tested in clinical
trials (Audeh et al. 2010; Tutt et al. 2010; Kaye et al.
2012). Recently, a specific inhibitor of the non-homologous
end joining (NHEJ)-associated DNA ligase IV has been
published (Srivastava et al. 2012) and showed great
potency in terms of radiosensitizing cancer cells both
in vitro and in vivo (Srivastava et al. 2012). Further studies
are needed in order to see whether this inhibitor is feasible
for clinical purposes.
Meanwhile, the small-molecule-inhibitor-based inter-
ference with DDR function might also offer the possibility
to specifically target cancer stem cells (CSCs)—a small
subset of the tumor cell population that shares several
features with normal stem cells, e.g., the potential to self-
renew, to proliferate excessively, to differentiate into
multiple cellular lineages, and to induce de novo formation
of blood vessels (Reya et al. 2001; Jordan et al. 2006).
CSCs have moved into the focus of targeted therapies in
recent years since complete eradication of a tumor inevi-
tably demands for elimination of this particular kind of
tumor cells that have the potential to self-renew and, in
consequence, exhibit clonogenicity. Notably, CSCs exhibit
an enormously high level of radioresistance (Bao et al.
2006; Firat et al. 2011), but the underlying mechanisms are
unknown. It has been suggested that lower levels of ROS
generated within the CSCs contribute to their high degree
of radioresistance as well as to their enormous capacity to
cope with DNA damages (Bao et al. 2006; Diehn et al.
2009). Very recently, it has been reported that CSCs
exhibit a great enhancement in ATM kinase activity, sug-
gesting that ATM might be a valuable target for combined
modality approaches aiming at overcoming CSC radiore-
sistance (Yin and Glass 2011). Indeed, Yin and Glass show
that the inhibition of ATM by a small-molecule inhibitor
reduces the radioresistance of CSCs (Yin and Glass 2011),
thereby offering novel therapeutic perspectives. Aside,
multiple signal transduction pathways that are important
for the development of non-transformed stem cells,
including the notch-, the hedgehog-, and the Wnt-/b-cate-
nin pathway, have been reported to contribute to radiore-
sistance in CSCs (Chen et al. 2007; Phillips et al. 2006;
Woodward et al. 2007; Wesbuer et al. 2010; Cerdan and
Bhatia 2010). This might offer additional prospects for
combinatorial approaches in future.
Combination of RTX with agents targeting topoisomerases
Topoisomerases represent a class of enzymes that regulate
the topology of DNA, e.g., during processes such as repli-
cation, transcription, recombination, and DNA repair. While
topoisomerase I (Topo I) coordinates relaxation of super-
helical DNA by introducing single-strand breaks (nicks)
within the DNA duplex, topoisomerase II (Topo II) intro-
duces transient double-strand breaks, thereby disentangling
coiled DNA (Champoux 2001). As these functions are cru-
cial both for the integrity and for the propagation of gen-
omes, topoisomerases became one of the first classes of
enzymes targeted in cancer therapy. Primarily, inhibitors
that were derived from camptothecin (inhibits topoisomer-
ase I) and etoposide/VP-16 (inhibits topoisomerase II) were
deployed to target the function of topoisomerases. Aside
from their immense chemotherapeutic potential per se, these
drugs also turned out to possess an excellent potential in
terms of sensitizing tumor cells toward ionizing radiation
(Chen et al. 1999). In parallel, several synthetic analogues,
such as topotecan and irinotecan, were raised and investi-
gated for clinical purposes (Pommier 2013). The results
obtained confirmed the notion that pharmaceutical inhibition
of topoisomerases provides a good opportunity for combined
modality treatment of multiple kinds of neoplasms (Mattern
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et al. 1991; Kim et al. 1992; Choy and MacRae 2001). This
explains why respective combinations have been and still are
enduringly tested within clinical trials (O’Leary and Muggia
1998; Hande 1998; Tao et al. 2013). In addition, multiple
other classes of topoisomerase inhibitors, such as quinolines
(inhibitors of topoisomerase I), quinolones, and anthracy-
clines (inhibitors of topoisomerase II), have been deployed
for clinical purpose (Pommier 2013).
Combination of RTX with agents targeting the apoptosis
network
As the induction of cell death—at least in part—depends
on the functionality of the apoptotic machinery, drugs that
can directly stimulate apoptosis (for instance, by facilitat-
ing caspase activation) also moved into the view of clini-
cally oriented research, especially as it can be assumed that
targeting of apoptotic network components should effi-
ciently sensitize tumor cells toward ionizing radiation.
Moreover, many kinds of tumor cells circumvent efficient
induction of apoptosis by down-regulation of pro-apoptotic
genes or up-regulation of antiapoptotic ones (Kasibhatla
and Tseng 2003). One prominent target among these
components is the TNF-a-related apoptosis-inducing
ligand (TRAIL/Apo2L). For several tumor cell lines, it
could be shown that both recombinant TRAIL itself and
TRAIL-receptor agonistic antibodies, e.g., mapatumumab
and lexatumumab, efficiently sensitize tumor cells to ion-
izing radiation (Belka et al. 2001; Chinnaiyan et al. 2000;
Gong and Almasan 2000; Marini et al. 2009a, b; Niyazi
et al. 2009a, b). In particular, cells that displayed only weak
responses to either treatment alone often showed strong
sensitization effects while no effect could be detected for
non-transformed cells, which is—at least in part—due to
the high level of selectivity of TRAIL and TRAIL-receptor
agonizing antibodies for malignant cells. Another class of
proteins involved in the regulation of apoptosis and
therefore representing a promising target for combined
modality approaches are the members of the B-cell lym-
phoma 2 (Bcl-2) family (Vogler et al. 2009). This protein
family regulates the permeabilization of the outer mito-
chondrial membrane—a prerequisite for apoptosis induc-
tion via the intrinsic pathway. Therefore, inhibition of
antiapoptotic Bcl-2 proteins should enhance the induction
of apoptosis, especially when being combined with irra-
diation. In fact, several studies showed that inhibition of
Bcl-2 sensitizes tumor cells toward ionizing radiation (Zerp
et al. 2009; Moretti et al. 2010), revealing that Bcl-2 and,
possibly, other members of this protein family may serve as
candidates for targeted approaches in the future. Currently,
navitoclax (ABT-263), a highly selective Bcl-2 inhibitor, is
tested in clinical trials, and initial results strengthen the
hope for its future implementation in the clinic (Gandhi
et al. 2011; Rudin et al. 2012). A third class of compounds
known to promote both intrinsic activation of apoptosis and
radiosensitization are phospholipid analogues, such as the
membrane-targeted alkylphosphocholines miltefosine and
perifosine (Hilgard et al. 1997; Unger et al. 1989). The
radiosensitizing capacity of this kind of drugs has already
been proven in multiple tumor entities (Gao et al. 2011;
Henke et al. 2012; Vink et al. 2006, 2007; Berkovic et al.
1997; Ruiter et al. 1999; Rubel et al. 2006).
Combination of RTX with agents targeting cell division
The cell cycle phase in which cell division takes place (M-
phase) is considered to be the most vulnerable state in
terms of radiotherapeutic intervention as it is well
acknowledged that the sensitivity of cells to ionizing
radiation peaks at this cell cycle stage (Sinclair and Morton
1966; Terasima and Tolmach 1963). Therefore and because
of the fact that tumor cells, in contrast to most other non-
transformed cell types, divide extensively, ancient
approaches already aimed at arresting tumor cells within
M-phase in order to achieve a maximum in radiosensitivity.
For this purpose, drugs mainly derived from natural origin,
such as taxol/paclitaxel, colchicine, and colcemid, were
initially used. These compounds interfere with microtubule
dynamics, thereby preventing accurate execution of cell
division which results in a permanent arrest of the cells
within M-phase. As to be expected, several of these drugs
exhibited synergistic effects when being combined with
exposure to ionizing radiation (Griem and Malkinson 1966;
Brues et al. 1940; Tishler et al. 1992; Milas et al. 1994,
1996; Milross et al. 1997). This is why some of them (e.g.,
taxol) not only are adopted in radiochemotherapy but even
still are in the focus of current clinical research (Pergolizzi
et al. 2011; Combs et al. 2012). However, these drugs not
only lack the level of specificity current therapies demand
for, but they also exhibit side effects, which, in worst case,
even limit the therapeutic effort. Progression through
M-phase and the process of cell division itself both depend
on the function of a multitude of cellular proteins including
many protein kinases, which offers great opportunities for
pharmaceutical intervention. In recent years, small-mole-
cule inhibitors targeting protein kinases, which function
more or less exclusively during cell division (e.g., Aurora
kinases and Polo-like kinases), were designed and tested
for their utility in combinatorial approaches. In these
studies, several compounds, e.g., the Aurora kinase inhib-
itors AZD1152 (Barasertib), VX-680 (Tozasertib), and
MLN8054, as well as the Polo-like kinase-1 inhibitor
BI2536, have proven radiosensitizing potential (Moretti
et al. 2011; Tao et al. 2008, 2009; Guan et al. 2007; Harris
et al. 2012), nourishing the hope for their future imple-
mentation in the clinic.
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Combination of RTX with agents targeting the heat shock
response
Heat shock proteins (HSPs) are molecular chaperones that
catalyze the proper folding of other proteins and thereby
avoid protein aggregations within cells. HSPs are often
overexpressed in tumor cells as these cells are character-
ized by an overall increased level of protein synthesis, thus
necessitating effective chaperone function in order to pre-
vent misfolding and/or aggregation of proteins in these
cells. In addition, HSP expression can be induced in
response to multiple physiological or environmental
insults, including irradiation, hypoxia, and/or chemical
stress (Young et al. 2004). In this context, HSPs frequently
function in an antiapoptotic fashion by associating with key
components of the apoptotic machinery, thereby interfering
with efficient apoptosis induction. For example, HSP70 and
HSP90 can interfere with caspase-dependent and caspase-
independent apoptosis induction as well as by binding to
the pro-apoptotic proteins Apaf-1 and apoptosis-inducing
factor (AIF) (Garrido et al. 2006).
These findings explain why compounds that obstruct
HSP function came into the focus of clinical research in
recent years. Initially, naturally derived inhibitors targeting
HSPs, such as geldanamycin and radicicol, were tested for
clinical purposes but turned out to exhibit fatal side effects
such as liver toxicity, thus precluding their implementation
in the clinic. Therefore, novel compounds have been
designed molecularly in order to minimize these kinds of
side effects concomitant with a maximum in HSP-inhibit-
ing capacity (Chiosis et al. 2006). Among those, inhibitors
of HSP90 such as 17-N-allylamino-17-demethox-
ygeldanamycin (17-AAG), 17-dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG), or NVP-
AUY922, in particular, exhibited convincing potential in
promoting tumor cell death as well as in sensitizing tumor
cells to ionizing radiation (Bisht et al. 2003; Bull et al.
2004; Russell et al. 2003; Machida et al. 2005; Matsumoto
et al. 2005; Kabakov et al. 2008; Stingl et al. 2010; Mil-
anovi et al. 2013).
Combination of RTX with agents targeting the EGFR
pathway
Another promising target for combined modality approa-
ches is the EGFR, one member of the epithelial tyrosine
kinase-associated membrane receptor family, and its
downstream signaling pathways (Davies et al. 1980).
Activation of EGFR leads to cell proliferation, inhibition of
apoptosis, and angiogenesis. EGFR expression is com-
monly increased in human cancers (Wernicke et al. 2010),
and preclinical evidence suggests a direct impact of EGFR
on the sensitivity of tumor cells toward ionizing radiation
(Milas et al. 2000; Akimoto et al. 1999). In accordance, the
expression of EGFR was reported to be up-regulated in
response to irradiation, which might attenuate the effec-
tiveness of fractionated radiotherapy (Fedrigo et al. 2011).
Indeed, overexpression as well as mutations in the EGFR
gene was shown to directly correlate with tumor radiore-
sistance and poor clinical prognosis (Lammering et al.
2004; Giralt et al. 2005). Therefore, the EGFR pathway
exhibits great influence on the overall effect that can be
achieved by clinical irradiation, which in turn offers great
opportunities for pharmaceutical intervention. Various
kinds of EGFR-inhibiting molecules, such as the mono-
clonal antibodies cetuximab and panitumumab as well as
the tyrosine kinase inhibitors erlotinib and gefitinib, have
been developed and demonstrated great therapeutic benefit
both in preclinical reports and in randomized clinical trials
when combined with ionizing radiation. Therefore, EGFR
inhibition meanwhile has become an established part of the
clinical routine in radiation oncology (Nieder et al. 2012).
Combination of RTX with agents targeting the tumor
micromilieu
Solid tumors are usually composed of tumor cells and
several other cell types that form the tumor micromilieu.
Both the formation and the progression of a solid tumor
depend on the tight interaction between transformed tumor
cells and the cells in the tumor microenvironment. By
secreting growth factors and cytokines that target endo-
thelial cells, fibroblasts, and other cell types within the
microenvironment, tumor cells actively shape their sur-
rounding milieu, for instance by inducing de novo forma-
tion of blood vessels and extracellular matrices (Carmeliet
and Jain 2011). Moreover, tumor cells can also acquire the
capacity to skew or evade antitumor immune responses and
even to induce a milieu of immune tolerance (Dunn et al.
2004).
The complex interplay between tumor cells and the
tumor stroma has strong impact on the tumor’s sensitivity
to exposure to ionizing radiation and, therefore, on long-
term tumor control following radiotherapeutic attendance.
In this respect, understanding the effects of ionizing radi-
ation on the tumor microenvironment rather than on iso-
lated tumor cells is one of the greatest interests in current
radiobiological science. One promising candidate for
radiotherapeutic approaches is the tumor microvasculature
(Garcia-Barros et al. 2003). Recent reports suggest that
directly targeting angiogenesis might increase the thera-
peutic ratio when being combined with irradiation (Beal
et al. 2011). In accordance, the monoclonal antibody bev-
acizumab, which blocks angiogenesis by preventing the
binding of VEGF to its respective receptor (Willett et al.
2004), significantly improves clinical outcome when
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combined with radiotherapy (Velenik et al. 2011; Shin
et al. 2011; Niyazi et al. 2012a), and similar results were
obtained for the VEGF-R inhibitor vandetanib and, pri-
marily, for the antiangiogenetic peptide cilengitide (Albert
et al. 2006; Williams et al. 2004; Brazelle et al. 2006;
Drappatz et al. 2010; Yang et al. 2010). However, a recent
phase III trial on cilengitide in combination with radio-
chemotherapy failed to show a significant increase in
overall survival in glioblastoma patients.
Another mediator of the microenvironment’s response
to irradiation is transforming growth factor-b (TGF-b),
which is activated in response to ROS (Barcellos-Hoff and
Dix 1996). TGF-b regulates the proliferation, the differ-
entiation, and the migration of cells (Massague´ et al. 2000)
and also contributes to metastasis and cell invasion (Heldin
et al. 2009; Pardali and Moustakas 2007). This explains
why interfering with TGF-b signaling may decrease tumor
cell growth, as well as their motility and their metastasizing
capacity (Ikushima and Miyazono 2010). Thus, inhibition
of TGF-b can actively modulate the tumors’ response to
ionizing radiation, thereby providing an interesting tool for
combinatorial approaches (Flanders and Burmester 2003;
Rabbani et al. 2003; Xavier et al. 2004).
Side effects
As exposure to ionizing radiation induces cell death,
radiotherapy inevitably coincides with side effects, includ-
ing degeneration of normal tissues, acute inflammation, and
even fibrotic tissue remodeling. The implementation of
modern techniques such as IMRT has greatly facilitated the
reduction in these classical kinds of side effects. On the
other hand, novel, combined modality approaches that
employ novel, molecularly designed compounds have led to
rise of new, so far unknown side effects.
Classical side effects
Both acute inflammation and chronic fibrosis are classical
side effects that coincide with the radiotherapeutic treat-
ment of neoplasms and may limit radiation doses and thus
the efficacy of the treatment (Abratt et al. 2004; Plathow
et al. 2004; Abdollahi et al. 2005). In some cases, e.g., lung
cancer, dose limitations due to the restricted tolerance of
normal tissues even preclude successful radiotherapy in
many patients with advanced disease progression
(McDonald et al. 1995; Rosenzweig et al. 2000). In gen-
eral, the severity of irradiation-induced pneumonitis
depends on treatment factors, such as totality of the dose,
the volume of irradiated lung, the schedule of fractionation,
and the chemotherapy administered (Taghian et al. 2001;
Rosen et al. 2001; Shi et al. 2010; Blom Goldman et al.
2010), but also on patient- and/or disease-related factors,
such as preexisting lung diseases, poor pulmonary function,
or genetic predispositions (Movsas et al. 1997; Mertens
et al. 2002; Abratt et al. 2004). However, the mechanisms
underlying these side effects are still poorly understood.
Although irradiation-induced primary damages in target
cells such as apoptosis and necrosis have been sufficiently
documented (Eriksson and Stigbrand 2010; McBride 1995),
subsequent biological reactions in irradiated organs are
quite sophisticated and not well defined (Lindroos et al.
1995; Zhang and Phan 1996). Recent studies suggest that
cytokine cascades that govern the signaling pathways
involved in irradiation response may play a pivotal role
within these processes (Pohlers et al. 2009; Li et al. 2007;
Lee et al. 2010), and a growing body of evidence demon-
strates an increased expression of cytokines in radiation-
induced pulmonary lesions (Johnston et al. 1996; Abdollahi
et al. 2005). Among these, some pro-inflammatory cyto-
kines such as the TNF- and the CD95 ligands are of
importance for acute inflammation (Johnston et al. 1996;
Heinzelmann et al. 2006), while others, such as TGF-b and
PDGF, are more involved in the regulation of chronic
fibrotic response (Abdollahi et al. 2005; Dancea et al. 2009).
Recently described strategies that directly interfere with
intracellular signaling pathways have revealed encouraging
results in terms of attenuating radiation-caused side effects
(Abdollahi et al. 2005; Anscher et al. 2008; Puthawala
et al. 2008). However, as the cytokine signaling pathways
that are activated in response to irradiation are broadly
overlapping, rather than being independent of each other, it
is unlikely that a complete blockage of these reactions can
be achieved by blocking only one of them (Li et al. 2009;
Wynn 2008). Thus, multitargeted agents should exhibit
higher effectiveness in attenuation of radiation-induced
inflammation and fibrogenesis.
Novel side effects due to employment of targeted
agents
With the increase in clinical relevance of novel, molecu-
larly targeted agents, novel kinds of side effects are
emerging (Niyazi et al. 2011b). Unfortunately, clinical data
that would allow the assessment of these side effects are
scarce. Additionally, the heterogeneity of both targeted
agents and study designs does not allow abstraction these
side effects. The examples presented here are meant to give
an insight into the wide variety of side effects that may
arise due to employment of targeted agents.
On the one hand, huge clinical trials exist for targeted
agents such as trastuzumab, a humanized monoclonal anti-
her-2/neu antibody approved for the treatment of her-2/
neu-positive breast cancers, showing no significant addi-
tional effects if being combined with radiation in a short-
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time follow-up (Halyard et al. 2009). On the other hand,
there are agents such as sorafenib or erlotinib belonging to
the group of kinase inhibitors for which toxicity data upon
combined usage are extremely rare. However, case reports
exist, in which combinational or sequential application of
radiotherapy and kinase inhibitors were shown to lead to
severe or even fatal toxicities such as diarrhea (Silvano
et al. 2008), bowel perforation (Peters et al. 2008), and
bronchial fistula (Basille et al. 2010).
The most prominent and rather well-documented exam-
ple of a non-classical side effect can be observed for the
EGFR-antagonizing antibody cetuximab which, for exam-
ple, has been successfully used in combination with radio-
therapy for the treatment of head and neck cancers (Bonner
et al. 2006). In the trial conducted by Bonner and colleagues,
a significant improvement in overall survival of patients that
were treated with radioimmunotherapy was observed when
compared to patients treated with radiotherapy alone. Dur-
ing this trial, the combinational treatment was reported to be
rather well tolerated; however, during the years of clinical
use, multiple reports pointing out an increase in skin toxicity
and cases of even severe skin toxicity have been published
(Walsh et al. 2011; Koutcher et al. 2009; Giro et al. 2009;
Berger and Belka 2008).
Another targeted agent that exemplifies the heteroge-
neity of putative toxicities is the VEGF-antagonizing
antibody bevacizumab that is used in combination with
radiotherapy in different anatomical regions. Promising
attempts were made in the combination of radiotherapy
with bevacizumab for the treatment of (recurrent) glio-
blastomas (Beal et al. 2011; Vredenburgh et al. 2012).
While no increased infield bleeding was reported for the
application of ionizing radiation to the CNS, some cases of
wound dehiscence of the previously operated site as well as
increased levels of toxicity at late stages with some cases of
optic neuropathy and one single case of Brown–Se´quard
syndrome have been documented (Gutin et al. 2009; Niyazi
et al. 2012a; Lai et al. 2008; Kelly et al. 2011). Concerning
the combination of bevacizumab and radiotherapy in case
of the gastrointestinal tract, some studies pointed out an
increased toxicity level, such as ischemic bowel compli-
cations (Lordick et al. 2006), mucosal tumor-associated
bleeding (Crane et al. 2010), GI-bleeding, ulceration
(Crane et al. 2010), and wound complications (Dipetrillo
et al. 2012). Finally, in case of the mediastinal region, an
increased rate of tracheoesophageal fistula has been
reported (Spigel et al. 2010).
Prognosis and prediction
To date, therapeutic decisions are taken on increasing
individualized and personalized bases. Important criteria in
this regard are markers that help to predict the overall
prognosis of the patient, the potential success of a particular
kind of therapy, and the occurrence of unwanted side effects.
In particular, the combination of ionizing radiation with
molecularly targeted agents requires an a priori identifica-
tion of patients that will benefit most (or at all) from a
respective therapy. Here, classical parameters such as age,
tumor node metastasis (TNM) stage, and histology of the
tumor might not be sufficient, and additional information
concerning the molecular tumor characteristics is needed in
order to find the best therapeutic approach for the individual
patient. ‘‘Prognostic’’ markers, in general, provide infor-
mation concerning the natural course of the respective dis-
ease independently of the treatment applied. In contrast, the
term ‘‘predictive’’ refers to markers for which it is likely that
a specific subgroup among the patient collective will benefit
from a certain intervention. For example, the EGFR1
mutation has a predictive value in adeno-NSCLC patients,
but not a prognostic one (Oldenhuis et al. 2008).
Biomarkers for tumors
In patients with malignant gliomas, it should be of standard
to test for the mutational status of the genes encoding for
isocitrate dehydrogenases 1 and 2 (IDH-1/-2) as well as for
codeletion of the 1p/19q loci. While mutations within the
IDH-1/-2 genes can be found in more than 70 % of all
primary astrocytomas (WHO grades II/III), oligodendro-
gliomas, and secondary glioblastomas, the respective
mutation rate is only about 5 % in primary glioblastomas
and mutations within IDH-1/-2 are associated with positive
clinical prognosis in astrocytoma and glioblastoma (Yan
et al. 2009; Combs et al. 2011). In parallel, the codeletion
of 1p/19q was shown to correlate with reduced tumor
aggressiveness and better response in anaplastic oligoden-
droglioma (Cairncross et al. 2006; Quon and Abdulkarim
2008; van den Bent et al. 2006). In addition, also the
methylation status of the O-(6)-methylguanine-DNA
methyltransferase (MGMT) gene promoter should be
investigated. MGMT is a DNA-repairing enzyme that
decreases the effects achievable by alkylating agent (e.g.,
temozolomide)-based chemotherapy (Esteller et al. 2000).
Temozolomide is routinely used for concomitant radio-
chemotherapy in malignant gliomas as it was shown that
combining temozolomide with radiotherapy results in sig-
nificant prolongation of patient survival (Hegi et al. 2005;
Stupp et al. 2009). As methylation of the MGMT promoter
represses the expression of MGMT, this leads to a better
response and thus, the methylation status of the MGMT
promoter should be tested in routine before starting a
temozolomide-based therapy.
Carcinogenesis in squamous cell carcinomas of the head
and neck (HNSCC) can be linked either to the frequent use
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of tobacco and alcohol or to human papillomavirus (HPV)
infection. In HPV-positive tumors, p53 and pRB tumor-
suppressor function is blocked by viral proteins called E6
and E7, respectively, culminating in high levels of genome
instability and increased expression of the senescence-
associated Cdk1-inhibitor p16Ink4a. Detection of the HPV
status can be accomplished by real-time PCR, and p16Ink4a
can be detected by immunohistochemistry (Snow and
Laudadio 2010). Approximately one-quarter of all HNSCC
patients are positive for HPV (Deacon et al. 1984), and in
oropharyngeal carcinomas, the prevalence of a positive
HPV status is even around 40 %. Moreover, HPV-positive
tumors not only genetically differ from negative ones
(Martinez et al. 2007), but they also differ in terms of
capacity to cope with DNA damage which is reduced in the
HPV-positive tumors (Rieckmann et al. 2013). This can
also explain, at least in part, why the HPV status is such an
important prognostic factor in HNSCC patients, as it is
often associated with superior outcome in case of patients
treated with surgery followed by adjuvant radiotherapy or
definitive radiochemotherapy (Ihloff et al. 2010; Fischer
et al. 2010; Prestwich et al. 2010).
Biomarkers for side effects
One limitation in the radiotherapeutic treatment for
malignant tumors is given by the need to minimize toxic
effects that may harm normal tissues. In this context, late
complications are of special importance because of fre-
quently showing progression and thus association with
long-life risk (Jung et al. 2001). Meanwhile, the extent of
tissue toxicity introduced by irradiation greatly varies
among different patients. Even though inherited hyper-
sensitivity syndromes such as ataxia telangiectasia and the
Nijmegen breakage syndrome that are characterized by
severe side effects are rare, a wide range of reactions
within normal tissues can be detected among the standard
population. It was suggested that such individual variations
in radiosensitivity are caused by genetic differences, such
as single nucleotide polymorphisms (SNPs) (Turesson
et al. 1996; Safwat et al. 2002). As these may serve as
markers that would allow for estimating the individual risk
of radiation-induced toxicity to non-transformed tissues,
extensive efforts were made to identify such markers.
Indeed, several SNPs could be identified that show tight
relation with the degree of radiotoxicity as exemplified by
SNPs that reside in the IL12RB2 and the ABCA1 genes
(Isomura et al. 2008) as well as within the ATM gene
(Edvardsen et al. 2007; Xiong et al. 2012). However, the
studies performed so far often give rise to heterogeneous
and/or even conflicting results. This can be seen for
instance by the C-509 T polymorphism, an extensively
studied SNP of the TGFb1-encoding gene, for which
conflicting results have been reported regarding its role in
promoting inflammatory and fibrotic effects (Quarmby
et al. 2003; Andreassen et al. 2005; De Ruyck et al. 2006;
Barnett et al. 2010; Martin et al. 2010). Moreover, it was
shown that significant coincidence of SNP occurrence and
tissue toxicity is only found when several SNPs and/or
other risk alleles are combined (Alsner et al. 2008; An-
dreassen et al. 2006; Zschenker et al. 2010). However,
these data also have been contradicted by other studies
(Raabe et al. 2012; Barnett et al. 2012). Therefore, ana-
lyzing the presence of SNPs as biomarkers that allow for
individual prediction of side effects is still far from routine.
Personalized medicine: imaging for prognosis
and prediction
[18F]FDG-PET imaging has become the standard in onco-
logic treatment over the recent years especially for staging
purposes due to its higher sensitivity and specificity if
being compared to conventional imaging modalities such
as CT and MRI. PET tracers may serve as prognostic and
predictive markers for estimating responsiveness to radio-
therapy or combined radiochemotherapy (Bussink et al.
2011). The outcome of head and neck cancer patients has
been related to standardized uptake value (SUV) changes
in PET imaging (Allal et al. 2004). Several tumor entities
have been described in which PET gives early information
as a marker for pathological response, especially in the
cases of rectal cancer (de Geus-Oei et al. 2009), NSCLC
(Pottgen et al. 2006), and esophageal cancer (Song et al.
2005). PET-CT was even described to be complimentary to
conventional CT scan and able to predict early recurrences
in breast cancer (Evangelista et al. 2011). Ongoing Hodg-
kin trials are in part based on PET imaging, and the
stratification in these trials is done according to PET pos-
itivity after several chemotherapy cycles; however, this has
still to be regarded as an experimental concept. Involved-
node radiotherapy has been proposed as a means to further
improve the therapeutic ratio by reduction of radiation-
induced toxicity (Kobe et al. 2010) substantially based on
proper PET/CT staging. Altogether, PET seems to be a
substantial part of personalized medicine providing prog-
nostic information and enabling the clinician to base
treatment strategies on this information.
Meanwhile, PET-CT has gained an important place in
radiotherapy planning (Yaromina and Zips 2010) as it
provides detailed information about the tumor microenvi-
ronment in addition to anatomical imaging. In first
instance, PET imaging data can be used for better delin-
eation of the target volume. A second strategy, dose
painting by contours (DPBC), consists in the creation of an
additional PET-based target volume that is then treated
with higher dose levels. In contrast, dose painting by
16 Radiat Environ Biophys (2014) 53:1–29
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numbers (DPBN) aims for a local variation in dose pre-
scription according to the variation in the PET signal
(Thorwarth et al. 2010). For instance, in case of lung
cancer, several approaches already are available that
directly depend on PET imaging (De Ruysscher et al.
2012). Currently, 11C-choline and occasionally 18F- or 11C-
acetate are used as tracers for prostate cancer, reflecting the
phospholipid metabolism (Pinkawa et al. 2011). 11C-cho-
line-PET/CT might be considered as the imaging modality
in radiation oncology to select and to delineate target
volumes extending the prostate gland or fossa. In con-
junction with IMRT and IGRT, it therefore might offer the
opportunity for a dose escalation to selected sites while
avoiding the irradiation of healthy tissues (Wurschmidt
et al. 2011), and although the underlying assumption that
PET correlates positively with more resistant subvolumes
is still not proven for the broad variety of cancer types, data
are coming forward that this is the case, e.g., in lung
cancer. One open question is whether selective boosting
with limited sensitivity of choline-PET indeed leads to
higher tumor control rates (Niyazi et al. 2010).
Several trials are on their way to test PET imaging pro-
spectively, e.g., in lung cancer [PET-PLAN trial (Flecken-
stein et al. 2011)]. For malignant gliomas, FET-PET has been
shown to significantly alter the target volumes (Niyazi et al.
2011a; Walter et al. 2012) and amino acid-PET in general,
including 11C-methionine (MET)-PET, which was shown to
be effective in target volume delineation (Grosu et al. 2005).
The observation that meningioma cells overexpress the
somatostatin receptor 2 (SSTR2) was the rationale to retro-
spectively analyze how far DOTATOC-PET/CT is helpful to
improve target volume delineation for IMRT (Gehler et al.
2009). Many other tumor types are currently under investi-
gation as PET provides additional information on tumor
extent, involvement of lymph nodes, and putative distant
metastases. Nevertheless, several problems have to be solved
in the future, such as the inclusion of dynamic analyses and
the correct procedures for thresholds.
Conclusions
Radiotherapy represents a crucial treatment option in the
treatment for malignant diseases. In the recent years, the
efficacy of radiotherapy has been improved by new tech-
niques, among which IMRT and IGRT may constitute the
most important ones. In parallel, novel approaches that
combine radiotherapy with molecularly designed agents
specifically targeting the hallmarks of cancer have been
deployed and revealed promising results both in preclinical
models and in clinical trials. However, employment of such
targeted agents often coincides with new kinds of side
effects demanding for biomarkers, which allow for detailed
patient stratification. As the current availability of such
markers is far from satisfying, efforts to identify novel
candidates must be increased. In parallel, research focusing
on multimodality approaches must be intensified as con-
ventional radiochemotherapy has reached its limits.
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